NeuroPace 10-Q Backs Q3 Results; Cash $49.2M vs $59.2M Debt, Covenants Intact
NPCE is trading near its 52-week low of $11.9 (34% below the low).
Summary
NeuroPace's Q3 10-Q confirms the $23.1 million revenue and lowered $91-92 million FY26 guidance already reported today, and shows $49.2 million of cash against $59.2 million of debt with the MidCap liquidity covenant now dependent on the revenue test.
Key Events · Earnings and Guidance · NPCE
-
Q3 Revenue Flat, Guidance Cut Stands
Revenue of $23.1 million versus $23.4 million a year ago, with full-year 2026 guidance at $91-92 million, down from $99.5-101.5 million.
-
Cash Below Debt, Covenant Test Shifts
Cash, equivalents and short-term investments of $49.2 million against $59.2 million of long-term debt; the MidCap agreement requires $60.0 million of liquidity until June 30, 2027, so compliance leans on trailing 12-month RNS revenue of $89.5 million versus a $73.7 million minimum.
-
Margins Improve, Loss Narrows
Gross margin rose to 84.3% from 82.1% and operating expenses fell 7% to $21.6 million, cutting the continuing-operations net loss to $3.3 million from $4.9 million.
-
DIXI Now Discontinued Operations
The DIXI Medical product line is presented as a discontinued operation effective June 30, 2026, removing its prior-year contribution of $4.0 million in quarterly revenue.
Analysis · NPCE · Industrial Applications And Services
The headline numbers were already out today via the 8-K: Q3 revenue of $23.1 million (down 1% year over year) and a full-year 2026 guidance cut to $91-92 million from $99.5-101.5 million. What this 10-Q adds is the balance-sheet reality behind that cut. Cash, equivalents and short-term investments total $49.2 million against $59.2 million of long-term MidCap debt, and the loan requires at least $60.0 million of liquidity until June 30, 2027 — meaning the company is already below that threshold and is relying on the revenue-based alternative test, which it currently passes with trailing 12-month RNS revenue of $89.5 million versus a $73.7 million minimum. The guidance cut matters here because the softer covenant path ($35.0 million liquidity) only applies if 2026 RNS revenue reaches $90.0 million, which the new $91-92 million total-revenue range leaves little room for. The quarter itself was operationally cleaner: gross margin rose to 84.3% from 82.1% and operating expenses fell 7%, narrowing the continuing-operations net loss to $3.3 million from $4.9 million.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NPCE was trading at $7.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $412.6M. The 52-week trading range was $11.90 to $19.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.